{"entity":{"id":"celestial-tncll","kind":"trial","name":"CELESTIAL-TNCLL","aka":[],"tldr":"CELESTIAL-TNCLL tests the next-generation all-oral doublet against the current fixed-duration standard, with results expected from late 2026.","summary":"CELESTIAL-TNCLL, trial NCT06073821 sponsored by BeOne, formerly BeiGene, is the phase 3 that tests the next-generation all-oral doublet of sonrotoclax and zanubrutinib against the fixed-duration standard of venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukaemia, with results expected from late 2026. It follows the BGB-11417-101 study, in which the doublet produced undetectable MRD in almost all treatment-naive patients by week 96 including high-risk genetics, its estimated primary completion is November 2026, and a companion trial tests the doublet against zanubrutinib alone. Whether a second-generation BCL-2 inhibitor improves on venetoclax in a randomised comparison is the question it will answer.","status":"active","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT06073821","url":"https://clinicaltrials.gov/study/NCT06073821"},{"label":"CLL Society update (July 2026)","url":"https://cllsociety.org/2026/07/an-update-on-sonrotoclax-plus-zanubrutinib-for-cll/"}],"tags":[],"related":[],"cancers":["cll","cll-treatment-naive"],"sections":[],"technologies":["bcl2-inhibitors","kinase-inhibitors"],"targets":["bcl2","btk"],"drugs":["sonrotoclax","zanubrutinib","venetoclax","obinutuzumab"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06073821","phase":"3","setting":"Previously untreated CLL/SLL: fixed-duration sonrotoclax + zanubrutinib vs venetoclax + obinutuzumab","sponsor":"BeOne (BeiGene)","started":"2023-11-11","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/celestial-tncll/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/"}],"technology":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"},{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/"}],"drug":[{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/"},{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"},{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}],"pairing":[{"id":"btki-plus-venetoclax-fixed-duration","kind":"pairing","name":"BTK inhibitor + venetoclax, fixed duration","route":"/pairings/btki-plus-venetoclax-fixed-duration/"}],"idea":[{"id":"idea-mrd-guided-stop-cll","kind":"idea","name":"MRD-guided treatment duration in CLL","route":"/ideas/idea-mrd-guided-stop-cll/"}]}}